Commerzbank Aktiengesellschaft FI Has $30.51 Million Position in Abbott Laboratories $ABT

Commerzbank Aktiengesellschaft FI lifted its position in Abbott Laboratories (NYSE:ABT) by 5.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 224,343 shares of the healthcare product maker’s stock after purchasing an additional 11,802 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Abbott Laboratories were worth $30,513,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hughes Financial Services LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories during the 1st quarter valued at $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the first quarter worth $30,000. JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories during the first quarter worth $32,000. Finally, Vision Financial Markets LLC bought a new stake in shares of Abbott Laboratories during the first quarter worth $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Stock Performance

ABT stock opened at $133.24 on Friday. The business’s fifty day moving average is $132.44 and its 200-day moving average is $131.52. The company has a market cap of $231.90 billion, a P/E ratio of 16.70, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the company earned $1.14 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ABT shares. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research report on Friday, July 18th. Morgan Stanley raised their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. BTIG Research decreased their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Finally, Leerink Partners assumed coverage on Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $146.24.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.